Category: St. Jude MedicalSyndicate content

St. Jude Medical halts Enlightn IV trial

December 10, 2013 by Brad Perriello

St. Jude Medical halts the Enlightn IV trial of its renal denervation technology just a few months after getting the green light to begin enrollment.

St. Jude Medical halts Enlightn IV trial

 St. Jude Medical (NYSE:STJ) is calling off the Enlightn IV trial of the next generation of its renal denervation technology, just a few months after it began.

Edwards Lifesciences' Sapien forecast misses expectations

December 10, 2013 by Brad Perriello

Edwards Lifesciences shares slide more than 5% after the medical device company forecasts sales for its flagship Sapien replacement heart valve for next year that miss analysts' expectations.

Edwards Lifesciences' Sapien forecast misses expectations

A conservative forecast for 2014 sent shares of Edwards Lifesciences (NYSE:EW) down more than 5% yesterday and kept them flat today, as the medical device company said it expects more competition next year for its flagship Sapien replacement heart valve.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

UPDATED: St. Jude to buy back $700M in outstanding shares, affirms outlook

December 10, 2013 by Arezu Sarvestani

The board of Minnesota medtech titan St. Jude Medical approves a $700 million share buyback and a 25¢ Q4 dividend as it affirms its outlook for the rest of the fiscal year.

St. Jude to buy back $700M in oustanding shares

St. Jude Medical's (NYSE:STJ) announced that it has approval from its board of directors to buy back up to $700 million shares' worth of its outstanding common stock, reporting in tandem that it expects to meet its revenue and per-share earnings guidance for the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic exec questions CardioMEMS Champion

December 4, 2013 by Brad Perriello

Medtronic's cardiac and vascular group president, Michael Coyle, questions CardioMEMS' implantable heart monitor, citing Medtronic's experience with its now-abandoned Chronicle monitor.

Medtronic exec questions CardioMEMS Champion

The Champion implantable heart monitor made by CardioMEMS might not prove as cost-effective as a non-invasive approach, at least according to Medtronic (NYSE:MDT) cardiac and vascular group president Michael Coyle.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

St. Jude Medical launches another neurostim trial, hits 52-week high

December 4, 2013 by Brad Perriello

St. Jude Medical launches another trial of its neurostimulation technology for treating chronic pain after its stock hits a 52-week high.

St. Jude Medical launches another neurostim trial, hits 52-week high

St. Jude Medical (NYSE:STJ), fresh off of a 52-week high for its share price, said it's launching another clinical trial of its neurostimulation technology for treating chronic pain.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

St. Jude Medical launches Prodigy neurostim trial for chronic pain

December 3, 2013 by Brad Perriello

St. Jude Medical launches a clinical trial of its Prodigy neurostimulation device for treating chronic pain.

St. Jude Medical launches Prodigy neurostim trial for chronic pain

St. Jude Medical (NYSE:STJ) said it launched a clinical trial of its Prodigy neurostimulator to examine the treatment of chronic pain.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

UPDATE: Unexpectedly strong ICD sales for Medtronic buoy Boston Scientific

November 19, 2013 by Brad Perriello

Shares of Boston Scientific gain after Medtronic's fiscal 2nd-quarter results reveal higher-than-expected sales for its implantable cardioverter defibrillators.

UPDATE: Unexpectedly strong ICD sales for Medtronic buoys Boston Scientific
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp